What is HC Wainwright’s Estimate for BCRX Q3 Earnings?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Research analysts at HC Wainwright upped their Q3 2026 EPS estimates for shares of BioCryst Pharmaceuticals in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will earn $0.15 per share for the quarter, up from their previous estimate of $0.05. HC Wainwright has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($2.25) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ FY2026 earnings at ($2.12) EPS, FY2027 earnings at $0.89 EPS, FY2028 earnings at $1.33 EPS, FY2029 earnings at $2.00 EPS and FY2030 earnings at $3.20 EPS.

Several other brokerages also recently commented on BCRX. JPMorgan Chase & Co. assumed coverage on BioCryst Pharmaceuticals in a report on Monday, July 13th. They set a “neutral” rating and a $12.00 target price on the stock. Citizens Jmp increased their price target on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a research note on Thursday, May 7th. Cantor Fitzgerald raised their price objective on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 30th. Royal Bank Of Canada lowered their price objective on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Finally, Wall Street Zen raised BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Eight research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $20.60.

BioCryst Pharmaceuticals Stock Up 2.1%

NASDAQ BCRX opened at $9.94 on Monday. The company has a market capitalization of $2.54 billion, a price-to-earnings ratio of -6.63 and a beta of 0.56. BioCryst Pharmaceuticals has a twelve month low of $6.00 and a twelve month high of $11.22. The stock has a fifty day simple moving average of $9.53 and a 200 day simple moving average of $8.86.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The company had revenue of $218.25 million for the quarter, compared to analyst estimates of $183.28 million. During the same quarter in the previous year, the business earned $0.15 earnings per share. BioCryst Pharmaceuticals’s revenue was up 33.6% compared to the same quarter last year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Royal Bank of Canada grew its holdings in BioCryst Pharmaceuticals by 2.4% during the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after acquiring an additional 1,458 shares during the period. Cetera Investment Advisers lifted its stake in shares of BioCryst Pharmaceuticals by 13.8% in the 4th quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 1,494 shares during the period. Captrust Financial Advisors lifted its stake in shares of BioCryst Pharmaceuticals by 7.4% in the 2nd quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock valued at $198,000 after purchasing an additional 1,527 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of BioCryst Pharmaceuticals by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 2,115 shares in the last quarter. Finally, Legato Capital Management LLC boosted its position in shares of BioCryst Pharmaceuticals by 10.0% during the 4th quarter. Legato Capital Management LLC now owns 23,949 shares of the biotechnology company’s stock valued at $187,000 after purchasing an additional 2,172 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.